Brief: ExpreS2ion Provides Update On Development Of Breast Cancer Vaccine Candidate AV001

ExpreS2ion Biotech Holding AB

18/08/2020 07:10

Aug 18 (Reuters) - ExpreS2ion Biotech Holding AB
 EXPRS2.ST :
    * EXPRES2ION PROVIDES UPDATE ON ANTICIPATED DEVELOPMENT OF
THE
BREAST CANCER VACCINE CANDIDATE AV001, INCLUDING A PROBABLE
CHANGE IN ITS OWNERSHIP STAKE IN ADAPTVAC
    * WISHES TO EXERCISE OPTION TO INLICENSE AV001 BEFORE IT
EXPIRES
ON FEBRUARY 26, 2021
    * EXERCISE OF OPTION IS SUBJECT TO COMPANY OBTAINING
NECESSARY
FINANCING TO FUND EXERCISE OF OPTION AND FURTHER PRECLINICAL
DEVELOPMENT OF AV001
    * IF SO, COMPANY EXPECTS TO BE ABLE TO SUBMIT AN APPLICATION
TO
START CLINICAL TRIALS IN FIRST HALF OF 2022
    * WILL TRANSFER 16 PERCENT OF ITS JOINT VENTURE OWNERSHIP IN
ADAPTVAC TO JOINT VENTURE PARTNER NEXTGEN VACCINES
    * FOLLOWING TRANFER WHICH CO WILL HOLD 34% AND NEXTGEN
VACCINES
66% OF ADAPTVAC WHEN OPTION TO IN-LICENSE AV001 IS EXERCISED

Source text for Eikon:  ID:nWkrjBbY8 
Further company coverage:  EXPRS2.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))